Nature's Toolbox for Alzheimer's Disease: A Review on the Potential of Natural Products as Alzheimer's Disease Drugs.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing registered clinical trials without formal systematic review or meta-analysis.
PubMed 38616012 · doi:10.1016/j.neuint.2024.105738
What was done
Authors reviewed clinical trials registered on ClinicalTrials.gov between 2011 and 2023 that evaluated natural product-based compounds for cognitive performance and biomarkers in Alzheimer's disease (AD). The review examined 13 compounds representing 7 distinct mechanisms of action.
What was found
The abstract reports no numerical values, trial counts, or participant counts. Qualitatively, it reports that no natural-based compounds are FDA-approved for AD; some compounds showed cognitive improvements that may not translate to AD pathology; endogenous compounds demonstrated better outcomes; and docosahexaenoic acid (DHA) and cerebrolysin showed the greatest potential among the 13 evaluated compounds.
Why it matters
This synthesis provides an overview of clinical-stage natural compounds for Alzheimer's disease, showing that despite biological rationale and favorable transport properties, current trial evidence supports use as supplements rather than approved disease-modifying therapeutics.
Limits
The abstract provides no sample sizes, effect sizes, or meta-analytic pooling. The underlying clinical trials were noted to be relatively short in duration for assessing progressive neurodegenerative disease pathways. Proposed synergistic effects and pharmacological advantages remain theoretical assertions in the abstract.
Cited by
- supports Cerebrolysin is marketed and sold in Europe, but is not approved for sale in the United States.